MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Income Statement 2011-2026 | CSII
Annual Income Statement Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
588 M | 815 M | 1.41 B | 1.54 B | 1.11 B | 1.03 B | 638 M | 943 M | 809 M | 427 M | 167 M | 238 M |
Shares |
39.2 M | 38.8 M | 34.3 M | 33.5 M | 33.1 M | 32.4 M | 32.5 M | 31.5 M | 28.3 M | 21.7 M | 18 M | 15.9 M |
Historical Prices |
15.3 | 21.1 | 41.3 | 37.6 | 35.4 | 23.8 | 28.4 | 8.36 | 37.7 | 35 | 15.8 | 9.05 |
Net Income |
-36.9 M | -13.4 M | -27.2 M | -255 K | 1.71 M | -1.79 M | -56 M | -32.8 M | -35.3 M | -24 M | -16.8 M | -11.1 M |
Revenue |
236 M | 259 M | 237 M | 248 M | 217 M | 205 M | 178 M | 182 M | 137 M | 104 M | 82.5 M | 78.8 M |
Cost of Revenue |
63.4 M | 61.1 M | 48.8 M | 47.7 M | 39.5 M | 39.4 M | - | - | - | - | - | - |
Gross Profit |
173 M | 198 M | 188 M | 200 M | 178 M | 165 M | 143 M | 142 M | 106 M | 79.5 M | 63.3 M | 62.5 M |
Operating Income |
-35.8 M | -11.9 M | -26.8 M | -825 K | 2.23 M | -1.54 M | -56.1 M | -32.6 M | -33.5 M | -22.4 M | -14.5 M | -8.81 M |
Interest Expense |
1.63 M | 1.74 M | 1.97 M | 1.68 M | 1.72 M | 500 K | - | 23 K | 1.03 M | 1.34 M | 1.36 M | 1.42 M |
EBITDA |
-32.1 M | -8.84 M | -23.8 M | 2.62 M | 6.17 M | 2.59 M | -41.8 M | -30.3 M | -32.1 M | -21.4 M | -13.6 M | -8.09 M |
Operating Expenses |
209 M | 210 M | 215 M | 201 M | 175 M | 167 M | 188 M | 175 M | 139 M | 102 M | 77.7 M | 71.3 M |
General and Administrative Expenses |
171 M | 167 M | 170 M | - | - | - | - | - | - | - | 66.4 M | 62.4 M |
All numbers in USD currency
Quarterly Income Statement Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
39.7 M | 39.6 M | 39.6 M | 39.3 M | 39.2 M | 39.1 M | 39.1 M | 38.9 M | 38.8 M | 38.7 M | 38.8 M | 34.1 M | 34.1 M | 33.9 M | 34.1 M | 33.9 M | 33.5 M | 33.4 M | 33.5 M | 33.4 M | 33.1 M | 33 M | 33.1 M | 32.7 M | 32.2 M | 33 M | 32.2 M | 33 M | 32.6 M | 32.2 M | 32.4 M | 32.2 M | 31.5 M | 31.3 M | 31.5 M | 31.3 M | 27.2 M | 24.8 M | 26 M | 21.5 M | 20.7 M | 17.7 M | 20.7 M | 20.4 M | 17.8 M | 17.5 M | 17 M | 17 M |
Net Income |
-7.89 M | -10.6 M | -18.5 M | -9.66 M | -8.97 M | -8.62 M | -17.6 M | -8.62 M | -56 K | -2.08 M | -56 K | -2.89 M | -3.4 M | -3.4 M | -3.4 M | -5.78 M | 492 K | 492 K | 492 K | -2.89 M | -413 K | -1.98 M | -413 K | -1.98 M | 1.04 M | -1.86 M | 1.04 M | -1.86 M | -15.2 M | -13.3 M | -15.2 M | -13.3 M | -5.27 M | -8.22 M | -5.27 M | -8.22 M | -8.66 M | -7.29 M | -8.66 M | -7.29 M | -5.77 M | -12.2 M | -5.77 M | -5.21 M | -4.14 M | -3.86 M | -4.14 M | -3.86 M |
Revenue |
61.5 M | 59.7 M | 121 M | 56.2 M | 59.1 M | 58.4 M | 118 M | 63.3 M | 64.2 M | 60.5 M | 64.2 M | 61.2 M | 68.3 M | 64.5 M | 68.3 M | 64.5 M | 60.2 M | 56.3 M | 60.2 M | 56.3 M | 52.6 M | 49.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
18.5 M | 16.7 M | 35.2 M | 14.8 M | 18.1 M | 14.3 M | 32.4 M | 14 M | 13.9 M | 12.6 M | 13.9 M | 12.2 M | 13.7 M | 12.7 M | 13.7 M | 12.7 M | 11.5 M | 10.6 M | 11.5 M | 10.6 M | 9.5 M | 9.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
43 M | 43 M | 86 M | 41.4 M | 41.1 M | 44.1 M | 85.1 M | 49.3 M | 50.2 M | 48 M | 50.2 M | 49 M | 54.6 M | 51.8 M | 54.6 M | 51.8 M | 48.7 M | 45.7 M | 48.7 M | 45.7 M | 43.1 M | 40.5 M | 43.1 M | 40.5 M | 40.9 M | 40.3 M | 40.9 M | 40.3 M | 33.3 M | 35.1 M | 33.3 M | 35.1 M | 35.4 M | 32.5 M | 35.4 M | 32.5 M | 25 M | 22.9 M | 25 M | 22.9 M | 19.4 M | 18 M | 19.4 M | 18 M | 15.2 M | 14.3 M | 15.2 M | 14.3 M |
Operating Income |
-8.53 M | -10.9 M | -19.4 M | -9.65 M | -8.56 M | -8.12 M | -16.7 M | -5.65 M | 283 K | -1.66 M | 283 K | -2.74 M | -3.37 M | -5.93 M | -3.37 M | -5.93 M | 384 K | -2.97 M | 384 K | -2.97 M | -275 K | -1.75 M | -275 K | -1.75 M | 1.08 M | -1.87 M | 1.08 M | -1.87 M | -15.1 M | -13.2 M | -15.1 M | -13.2 M | -5.25 M | -8.19 M | -5.25 M | -8.19 M | -7.5 M | -6.85 M | -7.5 M | -6.85 M | -5.12 M | -5.21 M | -5.12 M | -5.21 M | -3.66 M | -3.1 M | -3.66 M | -3.1 M |
Interest Expense |
404 K | 406 K | 810 K | 408 K | 409 K | 410 K | 819 K | 412 K | 412 K | 499 K | 412 K | 501 K | 500 K | 472 K | 500 K | 472 K | 422 K | 424 K | 422 K | 424 K | 430 K | 432 K | 430 K | 432 K | 46 K | - | - | - | - | - | - | 1 K | 6 K | 16 K | 22 K | 103 K | 564 K | 281 K | 564 K | 281 K | 345 K | 370 K | 345 K | 370 K | 279 K | 344 K | - | - |
EBITDA |
-8.18 M | -10 M | -17.6 M | -9.3 M | -8.21 M | -7.16 M | -14.8 M | -5.34 M | 587 K | -933 K | 1.76 M | -2.4 M | -3.04 M | -5.19 M | -1.88 M | -5.19 M | 439 K | -2.17 M | 1.96 M | -2.17 M | -275 K | -758 K | 1.71 M | -758 K | 1.08 M | -910 K | 3.02 M | -910 K | -15.1 M | -12.3 M | -13.3 M | -12.3 M | -5.25 M | -7.82 M | -4.5 M | -7.82 M | -7.5 M | -6.55 M | -7.39 M | -6.82 M | -5.12 M | -5.17 M | -5.12 M | -5.21 M | -3.66 M | -3.06 M | -3.66 M | -3.1 M |
Operating Expenses |
51.5 M | 53.9 M | 105 M | 51.1 M | 49.6 M | 52.2 M | 102 M | 54.9 M | 50 M | 49.6 M | 50 M | 51.7 M | 58 M | 57.8 M | 58 M | 57.8 M | 48.3 M | 48.7 M | 48.3 M | 48.7 M | 43.4 M | 42.2 M | 43.4 M | 42.2 M | 39.8 M | 42.2 M | 39.8 M | 42.2 M | 48.5 M | 48.3 M | 48.5 M | 48.3 M | 40.6 M | 40.7 M | 40.6 M | 40.7 M | 32.5 M | 29.7 M | 32.5 M | 29.7 M | 24.5 M | 23.2 M | 24.5 M | 23.2 M | 18.8 M | 17.4 M | 18.8 M | 17.4 M |
General and Administrative Expenses |
41.6 M | 44.5 M | 86.1 M | 41.7 M | 40.4 M | 41.9 M | 82.3 M | 41.4 M | 40.1 M | 40.3 M | 40.1 M | 41.4 M | 46.9 M | 46.8 M | 46.9 M | 46.8 M | 41.1 M | 41.2 M | 41.1 M | 41.2 M | 37 M | 35.9 M | 37 M | 35.9 M | 34 M | 36.9 M | 34 M | 36.9 M | 41.3 M | 41.4 M | 41.3 M | 41.4 M | 32.6 M | 33.5 M | 32.6 M | 33.5 M | 27.5 M | 25.4 M | 27.5 M | 25.4 M | 20.4 M | 20 M | 20.4 M | 20 M | 15.7 M | 15.4 M | 15.7 M | 15.4 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cardiovascular Systems (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
$ 11.24 | 3.12 % | $ 1.69 B |  USA |
 |
Cytosorbents Corporation
CTSO
|
$ 0.59 | -2.87 % | $ 36.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
$ 3.38 | 2.42 % | $ 127 M |  France |
 |
AxoGen
AXGN
|
$ 33.02 | 3.32 % | $ 1.52 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 1.95 | 3.17 % | $ 1.19 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Align Technology
ALGN
|
$ 179.33 | 3.58 % | $ 13.4 B | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 12.23 | 0.49 % | $ 1.65 B | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M |  China |
 |
IRIDEX Corporation
IRIX
|
$ 1.01 | 1.51 % | $ 17.1 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
$ 287.55 | 3.02 % | $ 8.11 B | USA |
 |
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
$ 39.05 | 3.88 % | $ 5.82 K | USA |
 |
LivaNova PLC
LIVN
|
$ 64.43 | 2.62 % | $ 3.51 B |  Britain |
 |
LENSAR
LNSR
|
$ 5.75 | 0.84 % | $ 68.8 M | USA |
 |
Boston Scientific Corporation
BSX
|
$ 62.92 | 1.83 % | $ 93.1 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
ClearPoint Neuro
CLPT
|
$ 9.95 | 14.57 % | $ 282 M | USA |
 |
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
$ 24.44 | 1.33 % | $ 207 M | USA |
 |
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | USA |
 |
Inogen
INGN
|
$ 6.47 | 2.21 % | $ 172 M | USA |
 |
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | USA |
 |
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | USA |
 |
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | USA |
 |
GBS
GBS
|
- | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
- | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
$ 16.82 | 5.32 % | $ 395 M | USA |
 |
Globus Medical
GMED
|
$ 92.99 | 2.84 % | $ 12.6 B | USA |
 |
Butterfly Network
BFLY
|
$ 4.23 | 2.92 % | $ 895 M | USA |
 |
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | USA |
 |
Stryker Corporation
SYK
|
$ 345.77 | 1.95 % | $ 132 B | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
TELA Bio
TELA
|
$ 0.55 | -3.07 % | $ 25.8 M | USA |
 |
Delcath Systems
DCTH
|
$ 10.42 | 3.78 % | $ 373 M | USA |
 |
Myomo
MYO
|
$ 0.71 | 3.41 % | $ 29.7 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 55.32 | 2.41 % | $ 1.62 B | USA |
 |
TransMedics Group
TMDX
|
$ 112.92 | -0.95 % | $ 3.84 B | USA |
 |
CONMED Corporation
CNMD
|
$ 38.1 | 3.7 % | $ 1.18 B | USA |